cagrilintide and semaglutide 2.4mg Efficacy safety of co-administered once-weekly 2·4 mg with once-weekly 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial Cagrilintide and Semaglutide: CagriSema Weight

A rat retinal ischemia study was conducted throughout 4 weeks, including fundoscopy, behavior presentation, tonometry, and histology assessment

Lysine fortification reduces anxiety and lessens stress in family members in economically weak communities in Northwest Syria

Ethics declarations Conflict of interest Mette JF Nielsen, Helene H Hansen Duus, Katrine Kirkeby, Britt W Lauenborg, Benjamin Low and Louise Witten are employees and stockholders of Novo Nordisk A/S

Cold Spring Harb Perspect Biol 7(11):a021733

(3)Fmoc-Gly-Leu-Val-WangResin (3) Preparation of Fmoc-Gly-Leu-Val-WangResin (2)Fmoc-Leu-Val-WangResin(20DMF)5203DMF3DMF2Fmoc-Gly-OH0.7gDIEA0.4mlTBTU0.56gHOBT0.2gDMF10ml1.53DMF3DMF2Fmoc-Gly-Leu-Val-WangResin In the Fmoc-Leu-Val-WangResin of step (2), add decapping reagent (DMF solution of 20% piperidine), react at room temperature for 5 minutes, drain, add decapping reagent at room temperature and react for 20 minutes, wash with isopropanol 3 times, washed 3 times with DMF, washed 2 times with re-distilled DMF, drained, added Fmoc-Gly-OH0.7g, DIEA0.4ml, TBTU0.56g, HOBT0.2g, DMF10ml, reacted at room temperature for 1.5 hours, pumped with a vacuum pump Dry, wash 3 times with isopropanol, wash 3 times with DMF, wash 2 times with DMF that has been distilled, and drain to obtain Fmoc-Gly-Leu-Val-WangResin